Thrombocytopenia During Venovenous Extracorporeal Membrane Oxygenation in Adult Patients With Bacterial, Viral, and COVID-19 Pneumonia.

Publication date: Jun 01, 2025

Contact of blood with artificial surfaces triggers platelet activation. The aim was to compare platelet kinetics after venovenous extracorporeal membrane oxygenation (V-V ECMO) start and after system exchange in different etiologies of acute lung failure. Platelet counts and coagulation parameters were analyzed from adult patients with long and exchange-free (≥8 days) ECMO runs (n = 330) caused by bacterial (n = 142), viral (n = 76), or coronavirus disease 2019 (COVID-19) (n = 112) pneumonia. A subpopulation requiring a system exchange and with long, exchange-free runs of the second oxygenator (≥7 days) (n = 110) was analyzed analogously. Patients with COVID-19 showed the highest platelet levels before ECMO implantation. Independent of the underlying disease and ECMO type, platelet counts decreased significantly within 24 hours and reached a steady state after 5 days. In the subpopulation, at the day of a system exchange, platelet counts were lower compared with ECMO start, but without differences between underlying diseases. Subsequently, platelets remained unchanged in the bacterial pneumonia group, but increased in the COVID-19 and viral pneumonia groups within 2-4 days, whereas D-dimers decreased and fibrinogen levels increased. Thus, overall platelet counts on V-V ECMO show disease-specific initial dynamics followed by an ongoing consumption by the ECMO device, which is not boosted by new artificial surfaces after a system exchange.

Concepts Keywords
Day Adult
Pneumonia Aged
Thrombocytopenia artificial surface
Viral coagulation disorder
COVID-19
dysfunction
ECMO
Extracorporeal Membrane Oxygenation
Female
Humans
Male
Middle Aged
platelet
Platelet Count
Pneumonia, Bacterial
Pneumonia, Viral
SARS-CoV-2
Thrombocytopenia
thrombocytopenia

Semantics

Type Source Name
disease MESH Thrombocytopenia
disease MESH COVID-19
disease MESH Pneumonia
disease IDO blood
pathway KEGG Platelet activation
disease MESH bacterial pneumonia
disease MESH viral pneumonia
drug DRUGBANK Fibrinogen Human

Original Article

(Visited 1 times, 1 visits today)